Gidaro, A.; Delitala, A.P.; Berzuini, A.; Soloski, M.J.; Manca, P.; Castro, D.; Salvi, E.; Manetti, R.; Lambertenghi Deliliers, G.; Castelli, R.
Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia. J. Clin. Med. 2022, 11, 4744.
https://doi.org/10.3390/jcm11164744
AMA Style
Gidaro A, Delitala AP, Berzuini A, Soloski MJ, Manca P, Castro D, Salvi E, Manetti R, Lambertenghi Deliliers G, Castelli R.
Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia. Journal of Clinical Medicine. 2022; 11(16):4744.
https://doi.org/10.3390/jcm11164744
Chicago/Turabian Style
Gidaro, Antonio, Alessandro Palmerio Delitala, Alessandra Berzuini, Mark J. Soloski, Pietro Manca, Dante Castro, Emanuele Salvi, Roberto Manetti, Giorgio Lambertenghi Deliliers, and Roberto Castelli.
2022. "Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia" Journal of Clinical Medicine 11, no. 16: 4744.
https://doi.org/10.3390/jcm11164744
APA Style
Gidaro, A., Delitala, A. P., Berzuini, A., Soloski, M. J., Manca, P., Castro, D., Salvi, E., Manetti, R., Lambertenghi Deliliers, G., & Castelli, R.
(2022). Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia. Journal of Clinical Medicine, 11(16), 4744.
https://doi.org/10.3390/jcm11164744
